All News

The approval was based on positive efficacy and safety indications from the IMforte clinical trial of patients with extensive-stage small cell lung cancer (SCLC).

FDA enhances oversight of drug ads using AI to ensure compliance, addressing risks and benefits in direct-to-consumer advertising.

Metabolic bariatric surgery offers greater weight loss and lower costs than GLP-1 treatments for obesity, prompting a reevaluation of treatment strategies.

Recent findings reveal that stereotactic radiation therapy (SABR) offers long-term survival outcomes comparable to surgery in patients with early non–small cell lung cancer (NSCLC).

Researchers uncover how apolipoprotein D (ApoD) increases influenza severity in older adults, highlighting the need for enhanced vaccines and new therapeutic strategies.

In chronic kidney disease (CKD), SDMA showed a stronger connection to vascular health compared with ADMA.

The RNA interference therapy indicated that, along with its therapeutic benefits in cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM), there was a reduced risk of GI events.

Gene therapy offers transformative potential in treating diseases like sickle cell and leukemia, highlighting pharmacists' crucial roles.

New research links oral bacteria and fungi to pancreatic cancer risk, suggesting oral microbiota as potential noninvasive biomarkers for early detection.

In an announcement at the White House, Pfizer said it will reduce drug prices in the United States to match those of other countries.

In this video, experts who attended the 2025 International Myeloma Society (IMS) Annual Meeting highlighted topics of interest as well as pivotal data.

A real-world study at MSK reveals promising efficacy and safety of second-generation BTK inhibitors in mantle cell lymphoma treatment, influencing future guidelines.

Pharmacists play a vital role in Breast Cancer Awareness Month, enhancing screening access and patient support through education and community engagement.

A federal pricing pact with Pfizer and an executive order on pediatric cancer AI may reshape affordability and evidence pathways for pharmacists and patients.

Explore the booming online pharmacy market for vitamins and supplements, and discover how pharmacists can guide patients in this digital landscape.

BATURA demonstrated that albuterol/budesonide significantly reduced severe exacerbation risk reduction in patients with mild asthma.

Remibrutinib gains FDA approval as the first oral treatment for chronic hives, offering hope for patients unresponsive to standard therapies.

Umoja Biopharma's UB-VV111 gains FDA fast track designation, revolutionizing CAR T-cell therapy for relapsed lymphoma and leukemia patients.

Cevostamab shows promise as a post-CAR T therapy for relapsed/refractory multiple myeloma, enhancing MRD-negative responses and improving patient outcomes.

AMT-130 demonstrates meaningful reductions in disease progression in the rare and chronic Huntington disease.

Recent trials reveal fam-trastuzumab deruxtecan-nxki's potential to transform treatment for patients with high-risk HER2-positive breast cancer, enhancing survival rates significantly.

Pharmacists should ensure pneumococcal vaccination strategies are tailored to high-risk individuals, especially those with type 2 diabetes (T2D).

Alice Wang, PharmD, BCOP, discusses the rapid infusion of isatuximab for multiple myeloma, highlighting its benefits, safety, and improved patient convenience in treatment.

Pharmacists explore virtual solutions for opioid use disorder, enhancing treatment retention and accessibility while addressing economic impacts.

Pharmacists lead the charge in integrating pharmacogenetics into patient care, overcoming education barriers and enhancing treatment outcomes through expert guidance.

New research reveals that eggs do not raise bad cholesterol; instead, saturated fat in the diet is the real culprit for heart disease.

Recent FDA approval of nirsevimab and clesrovimab have transformed RSV prevention in infants, prompting new recommendations from the CDC and AAP and replacing the long-standing role of palivizumab.